Lv11
88 积分 2024-10-12 加入
Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study)
18天前
已完结
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population
18天前
已完结
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
19天前
已完结
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC
19天前
已完结
Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
19天前
已完结
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy
19天前
已完结
Association of Metabolic‐Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study
19天前
已完结
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
9个月前
已完结
A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
9个月前
已完结
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
9个月前
已完结
皖公网安备34019202002308
